259 related articles for article (PubMed ID: 29203859)
1. Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme.
Newman JP; Wang GY; Arima K; Guan SP; Waters MR; Cavenee WK; Pan E; Aliwarga E; Chong ST; Kok CYL; Endaya BB; Habib AA; Horibe T; Ng WH; Ho IAW; Hui KM; Kordula T; Lam PYP
Nat Commun; 2017 Dec; 8(1):1913. PubMed ID: 29203859
[TBL] [Abstract][Full Text] [Related]
2. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.
Saikali S; Avril T; Collet B; Hamlat A; Bansard JY; Drenou B; Guegan Y; Quillien V
J Neurooncol; 2007 Jan; 81(2):139-48. PubMed ID: 17004103
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
4. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel role of IL-13Rα2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway.
Bhardwaj R; Suzuki A; Leland P; Joshi BH; Puri RK
J Transl Med; 2018 Dec; 16(1):369. PubMed ID: 30572904
[TBL] [Abstract][Full Text] [Related]
6. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
[TBL] [Abstract][Full Text] [Related]
7. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
Roos A; Dhruv HD; Peng S; Inge LJ; Tuncali S; Pineda M; Millard N; Mayo Z; Eschbacher JM; Loftus JC; Winkles JA; Tran NL
Mol Cancer Res; 2018 Jul; 16(7):1185-1195. PubMed ID: 29724813
[TBL] [Abstract][Full Text] [Related]
8. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
9. Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling.
Hsi LC; Kundu S; Palomo J; Xu B; Ficco R; Vogelbaum MA; Cathcart MK
Mol Cancer Ther; 2011 Jul; 10(7):1149-60. PubMed ID: 21596889
[TBL] [Abstract][Full Text] [Related]
10. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer.
Fujisawa T; Joshi BH; Puri RK
Int J Cancer; 2012 Jul; 131(2):344-56. PubMed ID: 21858811
[TBL] [Abstract][Full Text] [Related]
11. Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma.
Matsumoto Y; Ichikawa T; Kurozumi K; Otani Y; Fujimura A; Fujii K; Tomita Y; Hattori Y; Uneda A; Tsuboi N; Kaneda K; Makino K; Date I
Acta Neuropathol Commun; 2020 Apr; 8(1):42. PubMed ID: 32248843
[TBL] [Abstract][Full Text] [Related]
12. EGFR Signals through a DOCK180-MLK3 Axis to Drive Glioblastoma Cell Invasion.
Misek SA; Chen J; Schroeder L; Rattanasinchai C; Sample A; Sarkaria JN; Gallo KA
Mol Cancer Res; 2017 Aug; 15(8):1085-1095. PubMed ID: 28487380
[TBL] [Abstract][Full Text] [Related]
13. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL
Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897
[TBL] [Abstract][Full Text] [Related]
14. The EGFRvIII variant in glioblastoma multiforme.
Gan HK; Kaye AH; Luwor RB
J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
[TBL] [Abstract][Full Text] [Related]
15. The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1β-driven IL-6 secretion in glioblastoma cells.
Gurgis FM; Yeung YT; Tang MX; Heng B; Buckland M; Ammit AJ; Haapasalo J; Haapasalo H; Guillemin GJ; Grewal T; Munoz L
Oncogene; 2015 May; 34(22):2934-42. PubMed ID: 25088200
[TBL] [Abstract][Full Text] [Related]
16. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
[TBL] [Abstract][Full Text] [Related]
17. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
[TBL] [Abstract][Full Text] [Related]
18. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
19. Construction of IL-13 Receptor α2-Targeting Resveratrol Nanoparticles against Glioblastoma Cells: Therapeutic Efficacy and Molecular Effects.
Lin XM; Shi XX; Xiong L; Nie JH; Ye HS; Du JZ; Liu J
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638961
[TBL] [Abstract][Full Text] [Related]
20. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]